Short Term Corticosteroids in SARS-CoV2 Patients

Lifespan

Status: Completed

Conditions: SARS-CoV 2; Covid19; Steroids; Corticosteroids; Dexamethasone

Treatments: Drug: Dexamethasone

Study type: Observational

Funder types: Other

Identifiers

NCT04445506

20-027

Details and patient eligibility

About

The investigators reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone.

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Moderate disease with at least a 30% increase in CRP within 36 hours of admission, and with increasing oxygen requirements.
2. All patients with severe disease with evidence of escalating oxygen requirements
3. The presence of secondary bacterial infections as a probable cause of increasing CRP levels was excluded in all selected patients.
4. Pulmonary embolism and /or cardiac dysfunction were excluded as probable causes of worsening hypoxia in all selected patients.

Exclusion criteria

1. All patients on other treatment modalities- Remdesivir and/or Convalescent plasma who showed evidence of clinical improvement as per decrease in CRP levels and/or oxygen requirements were excluded.
2. Patient with associated COPD exacerbation who would benefit from the use of steroids.
3. Patients with Diabetic ketoacidosis, hyperglycemic hyperosmolar state, active concurrent bacterial infections.
4. Patients with history of steroid-induced mania and/or psychosis.

Trial design

50 participants in 1 patient group

SARS-CoV2 patients that received dexamethasone

Treatment:

Drug: Dexamethasone